Alphatec Holdings, Inc.
ATEC Healthcare Medical Devices
Alphatec Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $764.2 million, up 25.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.1%, EPS grew 40.7%, free cash flow fell 146.9% and total debt fell 7.79%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ATEC
Alphatec Holdings, Inc. (ATEC) EV/Sales
As of 16 October 2026, Alphatec Holdings, Inc. (ATEC) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from 0.3× (June 2017) to 8.7× (April 2021); the current reading is higher than 46% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.7× | 62.97% |
| FY2024 | 2.9× | (34.06%) |
| FY2023 | 4.3× | 0.98% |
| FY2022 | 4.3× | (15.95%) |
| FY2021 | 5.1× | (18.48%) |
| FY2020 | 6.3× | 88.34% |
| FY2019 | 3.3× | 213.51% |
| FY2018 | 1.1× | 104.84% |
| FY2017 | 0.5× | 14.94% |
| FY2016 | 0.5× | (40.24%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.2× | (17.06%) |
| Mar 2026 | 2.7× | (42.53%) |
| Dec 2025 | 4.7× | 30.28% |
| Sep 2025 | 3.6× | 18.47% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CNMD CONMED Corporation compare | 1.6× |
| INSP Inspire Medical Systems, Inc. compare | 1.9× |
| BVS Bioventus Inc. compare | 1.9× |
| NVCR NovoCure Limited compare | 2.0× |
| ATEC Alphatec Holdings, Inc. | 2.6× |
| UFPT UFP Technologies, Inc. compare | 3.8× |
| AXGN AxoGen, Inc. compare | 7.0× |
| ESTA Establishment Labs Holdings Inc. compare | 8.1× |
| BFLY Butterfly Network, Inc. compare | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)